TORONTO, Bayer Inc. announced today the Health Canada approval of Xarelto® (rivaroxaban tablet) in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate.(1) Xarelto® is the first once-daily oral anticoagulant for this indication that does not require routine coagulation monitoring. Xarelto® is also approved for the prevention of venous thromboembolic events (VTE), or blood clots, in patients who have undergone elective total hip or total knee replacement surgery and has become the number one dispensed anticoagulant prescribed by Canadian orthopedic surgeons in this indication.(2)